Mid career · publishing since 2004Rising activity
Sarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsGastrointestinal Tumor Research and TreatmentLymphoma Diagnosis and Treatment
Publications
140
Citations
8,135
Est. group size
~2
Recurring co-author estimate
Active years
23
Publishing since 2004
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 8,135p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 14.6p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~11 · 4% small-team papers (≤3 authors) · across 15 venues
Publication cadence
Publications per year over the last 10 years — averaging 14.6/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Factors Associated with Time to Sarcoma Diagnosis: Results from a Global Cross-Sectional Survey by the Sarcoma Patient Advocacy Global Network (SPAGN)
Cancers · 2026
- Factors Associated with Time to Sarcoma Diagnosis : Results from a Global Cross-Sectional Survey by the Sarcoma Patient Advocacy Global Network (SPAGN)
Open Collections · 2026
- 2712P Determinants of diagnostic intervals in sarcoma: Results from the global diagnosis pathway survey
Annals of Oncology · 2025
- Supplementary Data Table 2 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- Supplementary Data Table 3 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- Supplementary Data Table 4 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- Supplementary Data Table 5 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- Supplementary Data Table 1 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- Supplementary Data Table 6 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2025
- What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer
Cancers · 2024
- What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer
Preprints.org · 2024
- Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Clinical Cancer Research · 2023
- Data from Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
2023
- Data from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2023
- Data from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
2023
Publishes in
- Journal of Clinical Oncology×16
- Clinical Cancer Research×4
- Sarcoma×4
- Cancers×4
- The Lancet Oncology×2
Similar researchers
By research-topic overlap
- James Lin Chen
Medicine · The Ohio State University
- Scott M. Schuetze
Medicine · University of Michigan
- Scott Lenobel
Medicine · The Ohio State University
- Rashmi Chugh
Medicine · University of Michigan
- Nathan D. Seligson
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile